Board of Directors
Dr Ryan Cawood
Founder & Chief Executive Officer
Ryan founded Oxford Genetics in 2011, after earning a first class degree in genetics and a PhD from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™ that allowed researchers – for the first time – to assemble complex sections of DNA as simply as ‘molecular Lego’.
Martin Hall
Chief Financial Officer
Martin joined Oxford Genetics in November 2017 and has more than 30 years financial and general management experience in technology and IP-focused businesses. He specialises in leading and developing small technology organisations through periods of rapid growth, fund-raising and international expansion to exit events including trade sale or preparation for IPO.
Dr David Hames
Non-Executive Chairman
David has a first class degree and PhD in Biochemistry. Following postdoctoral research on eukaryotic gene transcription at the Institute for Cancer Research, Philadelphia, his academic research career centred on the control of developmental gene expression.
Prof Leonard Seymour
Founder and Non-Executive Director
Len is Professor of Gene Therapies at the University of Oxford and has over 25 years experience at the interface of genetic engineering and medicine. His main interests are in designing viruses and other micro-organisms for targeted cancer treatment.
Dr Mark Payton
Investor & Non-Executive Director
Mark is founder and Managing Director of Mercia Fund Management (MFM). He has a degree in Human Biology from Oxford, PhD from King's College London in molecular immunology and an MBA from Warwick Business School.
Dr Matthew Baker
Non-Executive Director
Dr Baker has a background in immunology with >15 years experience in developing biologics (for biotech and pharma companies), and has a successful track record of implementing M&A's and IPO exit strategies.